1. Introduction {#s0005}
===============

Lipomatous tumors arising from the uterus are extremely rare, accounting for 0.03% to 0.2%([@bb0010]) of all uterine tumors. They are generally classified as pure lipomas, mixed lipomas (e.g., lipoleiomyoma, angiolipoma, fibrolipoma), and liposarcomas. Liposarcomas are categorized into 4 groups by the World Health Organization classification system (2013): well-differentiated, dedifferentiated, myxoid, and pleomorphic subtypes ([@bb0030]).

A well-differentiated liposarcoma has a generally favorable prognosis; however, there is a 10% risk of dedifferentiation with local recurrence or metastasis ([@bb0030]). Therefore, forming an accurate preoperative diagnosis is very important, especially to distinguish this lesion from a benign lipoma. However, making an accurate diagnosis is difficult because liposarcoma, an especially well-differentiated type of neoplasm, is extremely rare in the uterine corpus and there are no reports of the definitive findings on preoperative imaging evaluation.

This is a report of an extremely rare instance of a well-differentiated liposarcoma developing in the uterine corpus. Herein, we describe the clinical, morphologic, and magnetic resonance imaging (MRI) features that typically determine the diagnosis. We also perform a review of the literature.

2. Case report {#s0010}
==============

A 55-year-old Japanese woman, gravida 6 para 3, presented to Dokkyo Medical University Hospital with the complaints of abdominal distension and genital bleeding. She underwent menopause at 53 years of age. She was followed by internal medicine for a history of a myocardial infarction, sleep apnea, diabetes mellitus, and dyslipidemia. Her family history was unremarkable. Her gynecologic history was significant for a uterine myoma, enlarged to the height of the umbilicus, at 45 years of age. At that time, she underwent treatment with a gonadotropin releasing hormone agonist to avoid surgery because of her medical complications; she was observed for 10 years after treatment. She then presented to our hospital with the complaint of abdominal distension.

Investigation using MRI revealed a 14.5 × 14-cm mass, unchanged compared with previous imaging. The radiologic diagnosis was leiomyoma or lipoleiomyoma. The MRI was repeated after 6 months because of her complaints of gradually increasing abdominal distension and postmenopausal genital bleeding. Repeat MRI revealed an obviously enlarged, solid tumor, 17 × 16 cm in diameter, occupying the uterine corpus. T1 and T2-weighted images showed high intensity in the tumor, and T1-weighted, fat-saturated images showed low intensity, suggesting this mass contained a fat component. A septum inside the tumor had a low signal on T1-weighted imaging and a high signal on T1-weighted imaging with fat saturation. The septum was enhanced on T1-weighted, fat-saturated, and gadolinium-enhanced imaging. The septum was nonuniform in thickness ([Fig. 1](#f0005){ref-type="fig"}). Diffusion-weighted imaging did not show any areas of abnormally high intensity, and an apparent diffusion coefficient map showed a high signal in some parts. Cervical and endometrial cytology were negative for malignancy. Based on these findings, the tumor was diagnosed as a uterine lipoma or lipoleiomyoma.Fig. 1Pelvic MRI findings. MRI revealed a solid tumor, 17 × 16 cm in diameter, occupying the uterine corpus. T1 and T2-weighted images showed high intensity in the tumor, and T1-weighted, fat-saturated images showed low intensity, suggesting this mass contained a fat component. A septum inside the tumor had a low signal on T1-weighted imaging and a high signal on T1-weighted imaging with fat saturation. The septum was enhanced on T1-weighted, fat-saturated, and gadolinium-enhanced imaging. The septum was nonuniform in thickness. (a; T2-weighted image, b; T1-weighted image, c; T1-weighted imaging with fat saturation, d; T1-weighted, fat-saturated, and gadolinium-enhanced imaging).Fig. 1

After obtaining informed consent, we performed a hysterectomy and bilateral salpingo-oophorectomy to relieve her complaints and to obtain a precise pathological diagnosis. Intraoperative inspection revealed the uterus to be round and enlarged to the size of over 15 cm in diameter, with a smooth surface; the ovaries and fallopian tubes appeared normal, and there were no other abnormalities noted. The tumor was encapsulated and well separated from the myometrium of the uterine corpus, occupying almost the entire corpus. The cut surface of the tumor was yellowish, with an elastic, soft consistency. There was a greyish part and a fibrous septum. There was no apparent hemorrhage or necrosis ([Fig. 2](#f0010){ref-type="fig"}a).Fig. 2Macroscopic findings and pathological examination. The tumor was encapsulated and well separated from the myometrium of the uterine corpus, occupying almost the entire corpus. The cut surface of the tumor was yellowish, with an elastic, soft consistency. There was a greyish part and a fibrous septum. There was no apparent hemorrhage or necrosis (a). Pathological examination revealed massive proliferation of mature adipocytes and spindle-shaped cells with atypia in the fibrous septum. Lipoblast-like atypical cells with relatively small, hyperchromatic, weakly pleomorphic nuclei and foamy or vacuolated cytoplasm were observed (*arrow*). There were no areas of hemorrhage, degeneration, or necrosis. Rare mitotic figures were seen in the tumor cells. Immunohistochemistry revealed that the tumor cells were weakly positive for MDM2 (*arrowhead*). (b; H&E, original magnification x4, c; H&E x10, d; H&E x40, e; MDM2 immunostaining x40).Fig. 2

Pathological examination revealed massive proliferation of mature adipocytes and spindle-shaped cells with atypia in the fibrous septum ([Fig. 2](#f0010){ref-type="fig"}b-e). Lipoblast-like atypical cells with relatively small, hyperchromatic, weakly pleomorphic nuclei and foamy or vacuolated cytoplasm were observed in the fibrous septum ([Fig. 2](#f0010){ref-type="fig"}b-e). There were no areas of hemorrhage, degeneration, or necrosis. Rare mitotic figures were seen in the tumor cells, with a mitotic count of \<1 per 10 high-power fields. The tumor itself was composed of nonepithelial cells with no apparent epithelial components. Immunohistochemistry revealed that the tumor cells were focally and weakly positive for mouse double minute 2 homolog (MDM2) and S-100 protein, and negative for phospho-histone H3 (PHH3). The labeling index of Ki-67 was 1%. The peritoneal washing cytology was negative for malignancy. The final pathologic diagnosis was a well-differentiated liposarcoma of International Federation of Gynecology and Obstetrics (FIGO) stage IB (pT1bNxM0).

After surgery, the patient underwent close follow-up without adjuvant therapy. She is currently alive 19 months after surgery, with no evidence of recurrence.

3. Discussion {#s0015}
=============

The incidence of lipomatous tumors in the uterus is low, and liposarcoma in particular is extremely rare. Many reported patients with liposarcoma have a neoplasm originating from the uterine cervix rather than the corpus. To the best of our knowledge, there are only 9 patients, including ours, reported in the English-language literature with a liposarcoma occurring in the uterine corpus([@bb0005]; [@bb0060]; [@bb0040]; [@bb0045]; [@bb0050]; [@bb0025]) ([Table 1](#t0005){ref-type="table"}). Patients with lipoleiomyosarcoma or mesenchymal malignant tumors having only a small part of liposarcomatous differentiation are excluded from this review.Table 1Liposarcoma of the uterine corpus: review of literature.Table 1AuthorsAge (years)SymptomsTumor size (cm)Preoperative diagnosisOperationHistological subtypeHisto-genesisFIGO stagePostoperative treatmentOutcomeBapat ([@bb0005])55Genital bleeding12x7x6N/AATH + BSO\
+PLN + PANMixed (myxoid+pleomorphic)+leiomyosarcomaN/AIBCT12 M\
RecSosnik ([@bb0060])71Genital bleeding10.8×12.9N/AATH + BSOPleomorphicN/AIBRT8Y\
NEDHong ([@bb0040])48Dysmenorrhea, abdominal mass21×18N/AATH + BSOMyxoidLeiomy-omaN/A--2 M\
NEDMcDon-ald ([@bb0045])49Abdominal mass10.5N/AATH + BSOPleomorphicLipoleio-myomaN/A--1Y\
NED58Genital bleeding18N/AATH + BSOMixed (myxoid+pleomorphic)Lipoleio-myomaN/A--2Y\
NED70Abdominal mass10N/AATH + BSOMyxoidLipoleio-myomaN/A--20Y\
NEDSchool-meeste ([@bb0050])70Dysuria9x8x7.5N/AMRH + BSO\
+PLNPleomorphicLipoleio-myomaN/ALung meta: CT (GEM\
+DTX)3 M\
DODFadare ([@bb0025])62Abdominal pain7 × 6.3×4.5Uterine fibroidATH + BSOPleomorphic+leiomyosarcomaLeiomy-omaN/ACT\
(after Rec)2 M\
RecPresent case58Abdominal distension, genital bleeding16 × 17Lipoleiomyo-ma or lipomaATH + BSOWell-differentiatedUnclearIB--1Y\
NED[^1]

The reason for the difference in incidence of liposarcoma of the uterine cervix versus the uterine corpus remains unclear. The corpus does not usually contain any adipose tissue, while adipose tissue is reportedly identified within the cervical stroma in about 15% of patients([@bb0015]). This anatomical and histological distinction may be one reason for the difference in the incidence of liposarcoma development between the cervix and the corpus.

There are various theories on how liposarcoma may develop from the uterine corpus: origination from pluripotential stem cells ([@bb0055]), malignant transformation of adipocytes in the myometrium from fat metaplasia of uterine mesenchymal tissue, migration of embryonic adipocytes or perivascular fat tissue, and transfer of adipocytes into the myometrium by manipulation ([@bb0060]; [@bb0025]). Malignant transformation from leiomyomata and lipoleiomyomata has also been reported ([@bb0045]; [@bb0025]). The pathogenesis of progression from a leiomyoma to a liposarcoma like as the present case is unclear; it is likely a malignant transformation of adipose metaplasia upon secondary degeneration of the leiomyoma.

Although most liposarcomas of soft tissue are well-differentiated, the subtypes of liposarcomas seen in the uterine corpus are of the myxoid or pleomorphic type (or a combination)([@bb0045]). Our patient, however, had a well-differentiated subtype ([Table 1](#t0005){ref-type="table"}). In our review of 8 reported patients with myxoid or pleomorphic liposarcomas, 3 relapsed or died, even with postoperative adjuvant chemotherapy. The biologic characteristics and optimal treatment strategy for these tumors, including possible chemotherapy regimens, has not been investigated because of the rarity of the lesions, and their prognosis remains unfavorable.

In contrast, well-differentiated types of soft-tissue tumors are lower-grade malignancies with a generally better prognosis, but even these have a risk for dedifferentiation with subsequent local recurrence and metastasis ([@bb0020]). Therefore, distinguishing these neoplasms from a lipoma, especially in the preoperative time period, is particularly important. Well-differentiated liposarcoma is characterized by amplification of the 12q13--15 region, and overexpression of the MDM2 and cyclin-dependent kinase 4 genes is useful in making the diagnosis ([@bb0045]). In our patient, immunostaining for MDM2 was slightly positive, supporting the histopathological diagnosis.

On MRI, pure lipomas generally do not have any nonadipose components, appearing as a homogeneous tumor with a large amount of fat and a decreased signal on fat- saturated imaging. In contrast, lipoleiomyoma has an inhomogeneous signal with fat and nonfat soft-tissue components; only part of the tumor demonstrates a decreased signal on fat-saturated imaging ([@bb0010]). To the best of our knowledge, this is the first report describing the detailed MRI findings in a liposarcoma developing from the uterine corpus.

Lipomas and liposarcomas usually occur in the extremities or the retroperitoneum. Reportedly, simple lipomas can be diagnosed with 100% specificity when the following 4 features are present on MRI: few or no thin septae, linear septae, no areas of enhancement, and no areas of high signal on T2-weighted imaging ([@bb0035]). In contrast, well-differentiated liposarcomas are diagnosed with 100% sensitivity and 83% specificity when the following 3 features are present on MRI: a thickened or nodular septum (generally \>2 mm), areas of enhancement, and areas of high signal on T2-weighted imaging ([@bb0035]). In hindsight, the MRI findings in our patient were consistent with these criteria. Therefore, these MRI criteria should be considered when forming the differential diagnosis in a patient with a uterine tumor containing adipose tissue. This is the same as for soft tissue nongynecologic neoplasms. In addition to these MRI findings, various symptoms, such as abdominal discomfort or genital bleeding, or postmenopausal enlargement of a uterine tumor may be useful signs of liposarcoma of the uterine corpus.

In conclusion, we describe herein a patient diagnosed with a rare liposarcoma originating from the uterine corpus. The rarity of liposarcoma of the uterine corpus poses a challenge for diagnosis and treatment. Currently, case reports and case series are the most viable option for characterizing this tumor and for developing optimal treatment strategies.
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[^1]: N/A: not applicable, MRH: modified radical hysterectomy, ATH: abdominal total hysterectomy, BSO: bilateral salpingo-oophorectomy, PLN: pelvic lymphadenectomy, PAN: paraaortic lymphadenectomy, OMT: omentectomy, meta: metastasis, RT: radiotherapy, GEM: gemcitabine, DTX: docetaxel, CT: chemotherapy, NED: no evidence of disease, DOD: dead of disease, Rec: recurrence.
